Adverse drug reactions : Neuraminidase inhibitors: widespread use for influenza may reveal more adverse effects

Anthony Cox*, Deborah Layton

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Both oseltamivir and zanamivir are safe drugs with relatively few adverse effects based on clinical trial data. A theoretical risk of bronchospasm with the use of inhaled zanamivir is of concern in those with respiratory disease and there is an unknown risk of very rare skin reactions to oseltamivir. Despite the concerns about neuropsychiatric events with the use of NAIs, and the inclusion of these in product literature, pharmacoepidemiogical studies and case report analysis cast doubt on such an association. Influenza infection is arguably the more plausible cause of neuropsychiatric events. Widespread use of NAIs, either for treatment or prophylaxis, may uncover further rare adverse reactions. Oseltamivir is currently a black triangle drug, under intensive surveillance by the Medicines and Healthcare products Regulatory Agency. All suspected adverse reactions, including non-serious ones, should be reported, even if the reaction is well recognised, or if the reporter is uncertain that the drug has caused it. In addition, any suspected adverse reactions in children to either drug should be reported to the MHRA via the Yellow Card Scheme.

Original languageEnglish
Pages (from-to)621-622
Number of pages2
JournalPharmaceutical Journal
Volume282
Issue number7553
Publication statusPublished - May 2009

Fingerprint

Neuraminidase
Drug-Related Side Effects and Adverse Reactions
Oseltamivir
Human Influenza
Zanamivir
Pharmaceutical Preparations
Bronchial Spasm
Clinical Trials
Delivery of Health Care
Skin
Infection
Therapeutics

Cite this

@article{570a1239e99e494d8c431e7eb225a5ea,
title = "Adverse drug reactions : Neuraminidase inhibitors: widespread use for influenza may reveal more adverse effects",
abstract = "Both oseltamivir and zanamivir are safe drugs with relatively few adverse effects based on clinical trial data. A theoretical risk of bronchospasm with the use of inhaled zanamivir is of concern in those with respiratory disease and there is an unknown risk of very rare skin reactions to oseltamivir. Despite the concerns about neuropsychiatric events with the use of NAIs, and the inclusion of these in product literature, pharmacoepidemiogical studies and case report analysis cast doubt on such an association. Influenza infection is arguably the more plausible cause of neuropsychiatric events. Widespread use of NAIs, either for treatment or prophylaxis, may uncover further rare adverse reactions. Oseltamivir is currently a black triangle drug, under intensive surveillance by the Medicines and Healthcare products Regulatory Agency. All suspected adverse reactions, including non-serious ones, should be reported, even if the reaction is well recognised, or if the reporter is uncertain that the drug has caused it. In addition, any suspected adverse reactions in children to either drug should be reported to the MHRA via the Yellow Card Scheme.",
author = "Anthony Cox and Deborah Layton",
year = "2009",
month = "5",
language = "English",
volume = "282",
pages = "621--622",
journal = "Pharmaceutical Journal",
issn = "0031-6873",
publisher = "Pharmaceutical Press",
number = "7553",

}

Adverse drug reactions : Neuraminidase inhibitors : widespread use for influenza may reveal more adverse effects. / Cox, Anthony; Layton, Deborah.

In: Pharmaceutical Journal, Vol. 282, No. 7553, 05.2009, p. 621-622.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adverse drug reactions : Neuraminidase inhibitors

T2 - widespread use for influenza may reveal more adverse effects

AU - Cox, Anthony

AU - Layton, Deborah

PY - 2009/5

Y1 - 2009/5

N2 - Both oseltamivir and zanamivir are safe drugs with relatively few adverse effects based on clinical trial data. A theoretical risk of bronchospasm with the use of inhaled zanamivir is of concern in those with respiratory disease and there is an unknown risk of very rare skin reactions to oseltamivir. Despite the concerns about neuropsychiatric events with the use of NAIs, and the inclusion of these in product literature, pharmacoepidemiogical studies and case report analysis cast doubt on such an association. Influenza infection is arguably the more plausible cause of neuropsychiatric events. Widespread use of NAIs, either for treatment or prophylaxis, may uncover further rare adverse reactions. Oseltamivir is currently a black triangle drug, under intensive surveillance by the Medicines and Healthcare products Regulatory Agency. All suspected adverse reactions, including non-serious ones, should be reported, even if the reaction is well recognised, or if the reporter is uncertain that the drug has caused it. In addition, any suspected adverse reactions in children to either drug should be reported to the MHRA via the Yellow Card Scheme.

AB - Both oseltamivir and zanamivir are safe drugs with relatively few adverse effects based on clinical trial data. A theoretical risk of bronchospasm with the use of inhaled zanamivir is of concern in those with respiratory disease and there is an unknown risk of very rare skin reactions to oseltamivir. Despite the concerns about neuropsychiatric events with the use of NAIs, and the inclusion of these in product literature, pharmacoepidemiogical studies and case report analysis cast doubt on such an association. Influenza infection is arguably the more plausible cause of neuropsychiatric events. Widespread use of NAIs, either for treatment or prophylaxis, may uncover further rare adverse reactions. Oseltamivir is currently a black triangle drug, under intensive surveillance by the Medicines and Healthcare products Regulatory Agency. All suspected adverse reactions, including non-serious ones, should be reported, even if the reaction is well recognised, or if the reporter is uncertain that the drug has caused it. In addition, any suspected adverse reactions in children to either drug should be reported to the MHRA via the Yellow Card Scheme.

UR - http://www.pharmaceutical-journal.com/learning/learning-article/adverse-drug-reactions-neuraminidase-inhibitors-widespread-use-for-influenza-may-reveal-more-adverse-effects/10964880.article

UR - http://www.scopus.com/inward/record.url?scp=77955870867&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77955870867

VL - 282

SP - 621

EP - 622

JO - Pharmaceutical Journal

JF - Pharmaceutical Journal

SN - 0031-6873

IS - 7553

ER -